Somaxon Pharmaceuticals Announces Acceptance of Phase 3 Clinical Trial Data for Publication in Sleep and Sleep Medicine

Published July 23, 2010

Somaxon Pharmaceuticals Announces Acceptance of Phase 3 Clinical Trial Data for Publication in Sleep and Sleep Medicine
SAN DIEGO—-Somaxon Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that detailed results from two Phase 3 clinical trials of the …
Read more on Business Wire via Yahoo! Finance